The SARS-CoV-2 Antibody Assay Monitoring (SAAM) program is designed to provide an external quality assurance (EQA) program to laboratories that are performing clinical endpoint assays for Phase 3 clinical trials in support of the US Government plan to develop countermeasures against SARS-CoV-3, formerly named Operation Warp Speed (OWS).
Thomas Denny, MSc,PHil